MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Pieris Pharmaceuticals Operating Cycle 2011-2026 | PIRS
Annual Operating Cycle Pieris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 64.3 | 29.1 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.3 | 29.1 | 46.7 |
Quarterly Operating Cycle Pieris Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 2.08 K | - | 4.67 | - | - | - | 7.04 | 20.3 | 20.6 | - | 106 | 259 | 51.1 | - | 53 | 13.8 | 29.2 | - | 40.9 | 116 | 50.7 | - | 29.5 | 21.1 | 201 | - | 361 | 766 | 530 | - | 6.69 | 4.9 | 2.11 | - | 1.91 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.08 K | 1.91 | 199 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Codexis
CDXS
|
70.7 | $ 1.93 | 6.04 % | $ 168 M | USA |
 |
Cerus Corporation
CERS
|
47 | $ 1.9 | 1.88 % | $ 362 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
656 | $ 1.69 | -2.31 % | $ 198 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
130 | $ 0.46 | -13.46 % | $ 5.27 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
178 | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.3 | 3.36 % | $ 227 M | Israel |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.6 | 0.95 % | $ 107 M | USA |
 |
Curis
CRIS
|
103 | $ 0.53 | -3.64 % | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 38.09 | 2.31 % | $ 3.58 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 49.43 | -0.17 % | $ 4.44 B |  Schweiz |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
CytomX Therapeutics
CTMX
|
12.2 | $ 4.41 | -3.4 % | $ 608 M | USA |
 |
Cue Biopharma
CUE
|
43.1 | $ 0.17 | -7.12 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
321 | $ 31.43 | 1.18 % | $ 2.09 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
120 | $ 4.34 | -29.51 % | $ 10.9 M | USA |